沙特克实验室
STTK
5.42
-0.11
-1.99%
沙特克实验室
US · STTK
#3662 按市值排名
上市于 2020
5.42
-0.11
-1.99%
实时 - 追踪5344个代码 - 心跳于23秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了1.5个百分点。
机构持股
- 机构持股比例
- 81.90% -1.54pp
- 机构数量
- 124 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund36.90%
Hedge Fund28.61%
VC/PE Fund13.71%
Individual/Insider6.96%
Family Office/Trust1.60%
Public Company0.74%
Private Company0.20%
Other11.16%
主要股东 截至 2026-06-30
T. Rowe Price Group, Inc.
16.02% · 16.07M 股
Adage Capital Management, L.P.
8.09% · 8.12M 股
OrbiMed Advisors LLC
6.28% · 6.31M 股
Prosight Management, LP
5.94% · 5.96M 股
Redmile Group, LLC
5.21% · 5.23M 股
BlackRock
3.92% · 3.94M 股
Frazier Life Sciences Management, LP
3.74% · 3.75M 股
Nextbio Capital Management LP
3.71% · 3.73M 股
Deep Track Capital, LP
3.69% · 3.71M 股
Vanguard Capital Management, LLC
3.66% · 3.67M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Josiah Hornblower | Co-Founder & Former Chairman of the Board | 2.97% |
| Taylor Schreiber | Chief Executive Officer | 2.72% |
| Clay Siegall | Director | 0.32% |
| Andrew Neill | Chief Financial Officer | 0.29% |
| Tyler Brous | Lead Independent Director | 0.24% |
| Arunthathy Pandite | Chief Medical Officer | 0.14% |
| Abhinav Shukla | Chief Technology Officer | 0.08% |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | 0.06% |
| George Golumbeski | Independent Chairperson | 0.05% |
| Neil W. Gibson | Independent Director | 0.05% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-05 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Retained | +12,153 | $3.57 |
| 2026-07-01 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Sale | -410 | $3.57–7.01 |
| 2026-06-30 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Sale | -23,465 | $3.57–7.08 |
| 2026-06-30 | Abhinav Shukla | Chief Technology Officer | Intent to Sell (Form 144) | -100 | $7.07 |
| 2026-06-29 | Arunthathy Pandite | Chief Medical Officer | Automatic Disposition | -30,000 | $7.01 |
| 2026-06-29 | Abhinav Shukla | Chief Technology Officer | Intent to Sell (Form 144) | -23,365 | $7.08 |
| 2026-06-10 | OrbiMed Advisors LLC | -- | Open Market Derivative Acquisiti | +1,250,000 | $0.00 |
| 2026-06-08 | Clay Siegall | Director | Open Market Acquisition | +62,500 | $4.00 |
| 2026-06-07 | OrbiMed Advisors LLC | -- | Other Derivative Acquisition | +18,439,788 | $0.00 |
| 2026-06-07 | Mona Ashiya | Director | Other Derivative Acquisition | +18,439,788 | $0.00 |
| 2026-05-28 | Clay Siegall | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Neil W. Gibson | Independent Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Mona Ashiya | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | George Golumbeski | Independent Chairperson | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Helen Boudreau | Independent Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Daniel Baker | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-21 | Clay Siegall | Director | Derivative Exercise and Retained | +128,054 | $1.08 |
| 2026-05-20 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Retained | +5,122 | $1.08 |
| 2026-05-14 | Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | Other Acquisition | +12,805 | $1.08 |
| 2026-05-11 | Taylor Schreiber | Chief Executive Officer | Derivative Exercise and Retained | +25,610 | $1.08 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
沙特克实验室 讨论区 0 条评论